In a multicenter phase 2 clinical trial, 101 patients diagnosed with various B-cell lymphomas including large B-cell lymphoma, primary mediastinal B-cell lymphoma, transformed follicular lymphoma all of which had refractory disease were dosed with the 2×106 anti-CD19 CAR T cells by the name of axi-cel. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.